Point72 Asset Management
FBLG icon

Point72 Asset Management’s FibroBiologics FBLG Stock Holding History

Point72 Asset Management’s Portfolio FBLG Stock Details FBLG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-724
Closed -$3.26K – 4630
2025
Q4 		$3.26K Buy
+724
New +$5.1K ﹤0.01% 3856

Other funds holding FBLG

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FEG
Fund Evaluation Group Cincinnati, Ohio $3.25B AUM 14.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CFP
Cascade Financial Partners San Diego, California $970M AUM 19.9% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
VGA
Vanguard Global Advisers Malvern, Pennsylvania $187B AUM

Point72 Asset Management's FBLG Position: Q1 2026 in Review

Point72 Asset Management sold out of FibroBiologics (FBLG) in Q1 2026, closing a stake of 724 shares — an estimated $3.26K sold.

Point72 Asset Management first reported a position in FBLG in Q4 2025 and held it in 1 quarter. The position peaked at $3.26K in Q4 2025. 17 funds tracked by Wall St. Rank hold FBLG as of Q1 2026.

  • Point72 Asset Management reported no remaining FibroBiologics position as of Q1 2026 after selling out during the quarter.
  • Point72 Asset Management sold 724 FibroBiologics shares in Q1 2026, an estimated $3.26K.
  • Point72 Asset Management first reported a position in FibroBiologics in Q4 2025 and held it in 1 quarter.
  • Point72 Asset Management's FibroBiologics position peaked at $3.26K in Q4 2025.
  • 17 funds tracked by Wall St. Rank held FibroBiologics as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.